Research analysts at Leerink Swann initiated coverage on shares of resTORbio (NASDAQ:TORC) in a report issued on Tuesday, February 20th, Marketbeat.com reports. The brokerage set an “outperform” rating and a $36.00 price target on the stock. Leerink Swann’s price target suggests a potential upside of 138.73% from the stock’s current price.
A number of other equities analysts also recently issued reports on the stock. Evercore ISI started coverage on shares of resTORbio in a report on Tuesday, February 20th. They set an “outperform” rating and a $28.00 price objective on the stock. Bank of America started coverage on shares of resTORbio in a report on Tuesday, February 20th. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Wedbush started coverage on shares of resTORbio in a report on Tuesday, February 20th. They issued an “outperform” rating and a $30.00 price target on the stock.
resTORbio (TORC) traded down $0.37 during midday trading on Tuesday, reaching $15.08. 247,804 shares of the company traded hands, compared to its average volume of 115,397. resTORbio has a twelve month low of $14.56 and a twelve month high of $21.10.
In related news, Director Orbimed Advisors Llc acquired 533,333 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $7,999,995.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Puretech Health Llc acquired 233,333 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was bought at an average price of $15.00 per share, for a total transaction of $3,499,995.00. The disclosure for this purchase can be found here.
ILLEGAL ACTIVITY WARNING: This article was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2018/03/15/restorbio-torc-coverage-initiated-by-analysts-at-leerink-swann.html.
resTORbio Company Profile
resTORbio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1).
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.